TH-302 has already been shown to improve mTOR-targeted therapies in renal cell carcinoma (Sun et al., 2015), and within our models, AZD2014 alone has demonstrated a clear survival benefit, equivalent to that of gemcitabine (Driscoll et al., 2016). Here, MTOR is linked to hereditary clear cell renal cell carcinoma.